Search Results 641-650 of 18060 for Alopecia

  1. A Study to Evaluate Binimetinib in Combination with Encorafenib in Patients with Pancreatic Malignancies and a Somatic BRAFV600E Mutation - Mayo Clinic

    EXCEPTIONS: Stable chronic conditions (≤ grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related ...

  2. Study to Compare the Safety and Effectiveness of Treatment Combinations in Patients with Recurrent Ovarian Cancer - Mayo Clinic

    Note: Patient with Grade ≤ 2 neuropathy or alopecia is an exception to this criterion and may qualify for the study. Patient has a known diagnosis of ...

  3. A Study of X4P-001 in Patients with Advanced Renal Cell Carcinoma - Mayo Clinic

    ... alopecia, TKI-related hand-foot syndrome, or thyroid dysfunction); Has had within the past 6 months the occurrence or persistence of one or more of the ...

  4. Sirolimus (oral route) - Side effects & dosage - Mayo Clinic

    Sirolimus is used together with other medicines to prevent the body from rejecting a transplanted kidney. It belongs to a group of medicines known as ...

  5. A Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination with Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14) - Mayo Clinic

    Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities, such as alopecia). Age 18 or ...

  6. Study Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphomas Using Nivolumab with or without Varlilumab - Mayo Clinic

    Patients who have not recovered to grade 1 or less from any adverse events due to agents administered more than 4 weeks earlier (excluding alopecia).

  7. Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations - Mayo Clinic

    therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity =< grade 2 - Albumin levels < 2.5 g/dl - Any of the following because this study ...

  8. Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

    Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the ...

  9. NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS - Mayo Clinic

    ... alopecia is not an exclusion);. - Radiotherapy within 14 days prior to the first dose of NKX101, or not recovered from acute toxic effects of radiotherapy ...

  10. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery - Mayo Clinic

    ... alopecia and grade 2 neuropathy are acceptable; Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; Patients must be ...